Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nevirapine + emtricitabine + tenofovir disoproxil fumarate
- Development stage
- Unknown
- Lead developer
- Viatris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**nevirapine + emtricitabine + tenofovir disoproxil fumarate** is a three-drug antiretroviral combination used primarily for the treatment of HIV-1 infection. All three components act as inhibitors of the HIV reverse transcriptase enzyme but belong to different classes: nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI); emtricitabine and tenofovir disoproxil fumarate are nucleos(t)ide reverse transcriptase inhibitors (NRTIs). The combination is favored for use in adults and in certain PMTCT (prevention of mother-to-child transmission) protocols, especially in resource-limited settings. Mechanistically, the three agents synergize to block HIV replication by targeting the viral reverse transcriptase at different sites and through different inhibitory mechanisms. There is no widely recognized brand name for this specific combination as a single co-formulated tablet, but it is often used as a regimen in clinical practice[7].
- Other names
- nevirapine + emtricitabine + tenofovir disoproxil fumarate
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on nevirapine + emtricitabine + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nevirapine + emtricitabine + tenofovir disoproxil fumarate.